Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Asset Writedowns and Impairment (2023 - 2024)

Historic Asset Writedowns and Impairment for Sangamo Therapeutics (SGMO) over the last 3 years, with Q2 2024 value amounting to $1.2 million.

  • Sangamo Therapeutics' Asset Writedowns and Impairment fell 9771.75% to $1.2 million in Q2 2024 from the same period last year, while for Mar 2025 it was $1.2 million, marking a year-over-year decrease of 9883.38%. This contributed to the annual value of $5.5 million for FY2024, which is 9383.03% down from last year.
  • Latest data reveals that Sangamo Therapeutics reported Asset Writedowns and Impairment of $1.2 million as of Q2 2024, which was down 9771.75% from $4.3 million recorded in Q1 2024.
  • Sangamo Therapeutics' 5-year Asset Writedowns and Impairment high stood at $51.3 million for Q2 2023, and its period low was $1.2 million during Q2 2024.